Table 3.
Therapy and Outcomes for Each Patient With LCCSCT Treated With Aromatase Inhibitors
| Therapy | Age at Start of Therapy | Total Time on Therapy | Change in Ht Percentile (Change in Ht sd) | Change in Bone Age (BA) and Predicted Adult Height (PAH)a | Change in Breast Size | Change in Testicular Sizeb |
||
|---|---|---|---|---|---|---|---|---|
| By Exam | By US | |||||||
| 1 | Ltzl 2.5 mg | 4.6 y | 6 mo | −0.1 (−0.4 sd) | BA: +0.5 y | R − 42 cm2, L − 52 cm2 | R − 2 mL, L + 2 mL | R + 1.9 mL, L + 0.4 mL |
| PAH: +0.8 cm | ||||||||
| 2 | Ltzl 2.5 mg | 5.1 y | 17 mo | −0.9 (−0.8 sd) | BA: None | −48 cm2 bilaterally | R no change, L + 1 mL | R − 0.1 mL, L + 2 mL |
| PAH: +5.9 cm | ||||||||
| 3 | Anzl 1 mg × 4 mo, | 8.5 y | 60 mo | −4.8 (−1 sd) | BA: +2.75 y | Full resolution | R − 2 mL, L − 2 mL | R − 1.4 mL, L − 0.9 mL |
| Anzl 1.5 mg × 10 mo, | OnA: −1.4 (−0.5 sd) | —OnA: +2.25 y | OnA: R − 11 cm2, L − 26.5 cm2 | OnA: R − 1 mL, L − 2 mL | ||||
| Ltzl 2.5 mg × 46 mo | OnL: −3.4 (−0.5 sd) | —OnL: +0.5 y | OnL: R − 9 cm2, L − 22.5 cm2 | OnL: R − 1 mL, L no change | ||||
| PAH: −10.8 cm | ||||||||
| 4 | Ltzl 2–3 mg | 8.7 y | 54 mo | −7.5 (−0.8 sd) | BA: +3 y | Full resolution (almost all within first year of treatment) | R − 2 mL, L no change | R + 9.2 mL, L + 0.1 mL |
| PAH: +23.3 cm | ||||||||
| 5 | Anzl 1 mg × 1 mo, | 10 y | 13 mo | −0.4 (0.2 sd) | BA: +1.5 y | Full resolution | Refused exam | R + 10.9 mL, L + 16.1 mL |
| Ltzl 2.5 mg × 12 mo | PAH: −13.6 cm | |||||||
| 6 | Ltzl 1.25 mg | 7.5 y | 6 mo | −1.8 (−0.4 sd) | BA: None | Small degree of decrease | R + 2–4 mL, (L removed) | R + 2.8 mL |
| PAH: +3.7 cm | ||||||||
Ltzl, Letrozole; Anzl, Anastrozole; mg, milligram; mo, months; y, years; Ht, height; sd, standard deviation; OnA, during time on anastrozole; OnL, during time on letrozole; R, right side; L, left side; cm, centimeters; mL, milliliters; US, ultrasound.
For patient 1, bone age data collected after 11 months of follow up; no data available from 17 month follow up visit.
For patients 3 and 4, change in testicular size is only evaluated from start of therapy until the last visit before onset of central puberty (36 months on treatment for patient 3 and 17 months for patient 4). Following onset of central puberty, both patients progressed to 25 mL testes bilaterally by physical exam.